FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Incorporated in 1984, Aarti Drugs Limited manufactures specialty chemicals and bulk drugs.
The company manufactures over 40 products comprising bulk actives, key intermediates, and specialty chemicals. Its product portfolio includes anti-biotic, anti-protozoal, anti-inflammatory, anti-fungal, anti-diabetic, cardio-protectant, vitamins, anti-arthritis, and sedative therapeutic groups that help in lifesaving and lifestyle-related diseases.
Aarti Drugs has nine manufacturing units located at Tarapur (Maharashtra) and two manufacturing units located at Sarigam (Gujarat), most of them being GMP certified. The company exports its products to over 100 countries worldwide. The Company has also got approvals from various authorities such as WHO-GMP, ACCREDITATION from JAPAN, IDL China, ANVISA, TGA Australia, COFEPRIS, and COS.
The company recorded a total revenue of Rs 2,71,824.75 lakhs, Rs2,49,996.17 lakhs, and Rs 2,15,930.50 lakhs in 2023, 2022, and 2021 respectively.
Issue Period | |
Security Name | Aarti Drugs Ltd. |
Issue Type | Tender Offer |
Issue Size (Shares) | 665,000 (0.72 % of Total number of equity Shares) |
Issue Size (Amount) | ₹59.85 Crores |
Buyback Price | ₹900 per share |
Face Value | ₹10 per share |
Listing At | BSE, NSE |
Last Date to buy shares | September 4, 2024 |
Record Date | September 5, 2024 |
Offer Opens On | |
Last Date for receipt of Tender Forms | |
Offer Closes On * | |
Finalisation of Buyback Acceptance | |
Last Date for settlment of bids | |
Last Date for Extinguishment of Shares |
Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 | |||||||||||||||||||||||||||
Assets | 2,421.4 | 2,207.96 | 1,766.01 | |||||||||||||||||||||||||||
Revenue | 2,718.25 | 2,499.96 | 2,159.31 | |||||||||||||||||||||||||||
Profit After Tax | 166.36 | 205 | 280.4 | |||||||||||||||||||||||||||
Amount in ₹ Crore |
The Company is proposing the Buyback to service the equity more efficiently. Additionally, the Company's management strives to increase equity shareholders value and the Buyback would result in, amongst other things:
2 The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares;
3 The Buyback is generally expected to improve return on equity through the distribution of cash and improve earnings per share by reduction in the equity base, thereby leading to long term increase in shareholders' value;
4 The Buyback gives an option to the shareholders holding Equity Shares of the Company, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment; and
5 The Buyback, which is being implemented through the tender offer as prescribed under the Buyback Regulations, would involve a minimum reservation of 15% for Small Shareholders and allocation of a higher number of shares as per their entitlement or 15% of the number of shares to be bought back, reserved for the Small Shareholders.
Sorry, we couldn't find any reviews, please check back later.
Aarti Drugs Ltd.
Plot No N-198
MIDC, Tarapura
Tal-Palghar, Dist Palghar-401506
Phone: 022-24072249
Email: admin@aartidrugs.com
Website: https://www.aartidrugs.co.in/
Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083
Phone: +91-22-4918 6270
Email: aarti.drugs.buyback2024@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Lead Manager(s)
Registered Broker
The Aarti Drugs Buyback 2024 open and close dates are not available as of now.
Last date to be eligible to participate in buyback is September 4, 2024.
The Aarti Drugs Buyback 2024 is a Tender Offer.
Sorry the Aarti Drugs Buyback 2024 timelines are not available at this time.
The Aarti Drugs Buyback 2024 is being offered at Rs ₹900 per share per equity share.
The record date for the Aarti Drugs Buyback 2024 is September 5, 2024.
The issue size of Aarti Drugs Buyback 2024 is of 665,000 equity shares at ₹900 per share aggregating upto ₹59.85 Crores.
The Company is proposing the Buyback to service the equity more efficiently. Additionally, the Company's management strives to increase equity shareholders value and the Buyback would result in, amongst other things:
2 The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares;
3 The Buyback is generally expected to improve return on equity through the distribution of cash and improve earnings per share by reduction in the equity base, thereby leading to long term increase in shareholders' value;
4 The Buyback gives an option to the shareholders holding Equity Shares of the Company, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment; and
5 The Buyback, which is being implemented through the tender offer as prescribed under the Buyback Regulations, would involve a minimum reservation of 15% for Small Shareholders and allocation of a higher number of shares as per their entitlement or 15% of the number of shares to be bought back, reserved for the Small Shareholders.
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Aarti Drugs Buyback 2024 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|